In this study, we compared the effects of the Src inhibitor dasatinib on the urothelial cancer cell line RT112 and its gemcitabine-resistant sub-line RT112rGEMCI20 in cell culture and in an orthotopic bladder cancer xenograft model in mice. The gene discussed is SRC; the disease is urinary bladder cancer.